{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:18:32Z","timestamp":1792685912094,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1R38HL143605-01"],"award-info":[{"award-number":["1R38HL143605-01"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K08CA252883"],"award-info":[{"award-number":["K08CA252883"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007747","name":"University of Utah","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clml.2024.07.013","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T17:04:08Z","timestamp":1722445448000},"page":"843-851","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Chronic Myelomonocytic Leukemia and Atypical Chronic Myeloid Leukemia: A National Analysis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8117-1295","authenticated-orcid":false,"given":"Victoria A.","family":"Vardell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Ose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2148-162X","authenticated-orcid":false,"given":"Anton V.","family":"Rets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas K.","family":"Tantravahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5374-3831","authenticated-orcid":false,"given":"Ami B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.clml.2024.07.013_bib0001","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1182\/blood-2018-10-844670","article-title":"MDS overlap disorders and diagnostic boundaries","volume":"133","author":"Tanaka","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.07.013_bib0002","series-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","year":"2001"},{"issue":"2","key":"10.1016\/j.clml.2024.07.013_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2019.101132","article-title":"Myelodysplastic\/myeloproliferative neoplasm, unclassifiable (MDS\/MPN-U): more than just a \u201ccatch-all\u201d term?","volume":"33","author":"Shallis","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"issue":"17","key":"10.1016\/j.clml.2024.07.013_bib0004","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1002\/cncr.33622","article-title":"Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia","volume":"127","author":"Montalban-Bravo","year":"2021","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.clml.2024.07.013_bib0005","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2024.07.013_bib0006","doi-asserted-by":"crossref","first-page":"142","DOI":"10.36401\/JIPO-21-1","article-title":"Chronic myelomonocytic leukemia: hematopathology perspective","volume":"4","author":"El Hussein","year":"2021","journal-title":"J Immunother Precis Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.07.013_bib0007","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.07.013_bib0008","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue","year":"2008"},{"key":"10.1016\/j.clml.2024.07.013_bib0009","series-title":"World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"issue":"7","key":"10.1016\/j.clml.2024.07.013_bib0010","doi-asserted-by":"crossref","first-page":"E246","DOI":"10.1002\/ajh.26182","article-title":"Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS\/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS)","volume":"96","author":"Montalban-Bravo","year":"2021","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.clml.2024.07.013_bib0011","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/10428194.2019.1691202","article-title":"Concurrent JAK2 V617F and MPL W515L in myelodysplastic\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis","volume":"61","author":"Ye","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.clml.2024.07.013_bib0012","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2024.07.013_bib0013","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.07.013_bib0014","unstructured":"National Cancer Institute, DCCPS, Surveillance Research Program. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Populations - Total U.S. (1969-2020) - Linked To County Attributes - Total U.S., 1969-2020 Counties. Published online 2022. https:\/\/seer.cancer.gov."},{"key":"10.1016\/j.clml.2024.07.013_bib0015","unstructured":"American College of Surgeons Commission on Cancer. National cancer database, 2020 participant user file. 2022. www.facs.org\/cancer\/ncdb."},{"key":"10.1016\/j.clml.2024.07.013_bib0016","year":"2021","journal-title":"IBM SPSS Statistics for Windows."},{"issue":"6","key":"10.1016\/j.clml.2024.07.013_bib0017","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/0962280206070621","article-title":"Efficient interval estimation for age-adjusted cancer rates","volume":"15","author":"Tiwari","year":"2006","journal-title":"Stat Methods Med Res"},{"issue":"5","key":"10.1016\/j.clml.2024.07.013_bib0018","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.clml.2024.07.013_bib0019","unstructured":"National Cancer Database Participant User File 2020 Data Dictionary. Commission on Cancer; 2022. https:\/\/www.facs.org\/media\/brilfbgu\/puf-2020-data-dictionary.pdf."},{"issue":"3","key":"10.1016\/j.clml.2024.07.013_bib0020","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.14061","article-title":"Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001-12","volume":"174","author":"Srour","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2024.07.013_bib0021","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canep.2016.03.011","article-title":"Myeloid malignancies in the real-world: occurrence, progression and survival in the UK's population-based Haematological Malignancy Research Network 2004-15","volume":"42","author":"Roman","year":"2016","journal-title":"Cancer Epidemiol"},{"issue":"2","key":"10.1016\/j.clml.2024.07.013_bib0022","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.leukres.2014.11.025","article-title":"The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands","volume":"39","author":"Dinmohamed","year":"2015","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.clml.2024.07.013_bib0023","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.3324\/haematol.2017.183160","article-title":"The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic\/myeloproliferative neoplasms","volume":"103","author":"Meggendorfer","year":"2018","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.clml.2024.07.013_bib0024","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.3324\/haematol.2018.208082","article-title":"Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation","volume":"104","author":"Patnaik","year":"2019","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.clml.2024.07.013_bib0025","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.clml.2024.07.013_bib0026","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","article-title":"Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia","volume":"121","author":"Such","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.07.013_bib0027","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/ajh.24396","article-title":"Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management","volume":"91","author":"Patnaik","year":"2016","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2024.07.013_bib0028","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/bjh.14619","article-title":"Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation","volume":"177","author":"Onida","year":"2017","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2024.07.013_bib0029","doi-asserted-by":"crossref","DOI":"10.1111\/j.1751-553X.2011.01351.x","article-title":"Clinical course and molecular features in 21 patients with atypical chronic myeloid leukemia","volume":"34","author":"Koldehoff","year":"2012","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.clml.2024.07.013_bib0030","doi-asserted-by":"crossref","first-page":"S345","DOI":"10.1016\/j.clml.2019.07.352","article-title":"Demographics and survival in atypical chronic myeloid leukemia: SEER data analysis","volume":"19","author":"Anusim","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"10.1016\/j.clml.2024.07.013_bib0031","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1200\/JCO.19.00895","article-title":"Efficacy of ruxolitinib in patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia","volume":"38","author":"Dao","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.07.013_bib0032","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ajh.24972","article-title":"A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome\/myeloproliferative neoplasms","volume":"93","author":"Assi","year":"2018","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2024.07.013_bib0033","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1182\/hematology.2020000163","article-title":"Myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes: a focused review","volume":"2020","author":"Patnaik","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"10.1016\/j.clml.2024.07.013_bib0034","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejogrb.2007.01.006","article-title":"Why do women live longer than men?","volume":"133","author":"Eskes","year":"2007","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"10","key":"10.1016\/j.clml.2024.07.013_bib0035","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1158\/1078-0432.CCR-04-2135","article-title":"Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes","volume":"11","author":"Kaminskas","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.clml.2024.07.013_bib0036","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ajh.27271","article-title":"Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management","volume":"99","author":"Patnaik","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2024.07.013_bib0037","doi-asserted-by":"crossref","first-page":"10767","DOI":"10.1038\/ncomms10767","article-title":"Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents","volume":"7","author":"Merlevede","year":"2016","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.clml.2024.07.013_bib0038","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.22.00437","article-title":"Decitabine versus hydroxyurea for advanced proliferative chronic myelomonocytic leukemia: results of a randomized Phase iii trial within the EMSCO network","volume":"41","author":"Itzykson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2024.07.013_bib0039","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/ajh.25488","article-title":"Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients","volume":"94","author":"Coston","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2024.07.013_bib0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.healthplace.2018.08.010","article-title":"Rural dwellers are less likely to survive cancer - an international review and meta-analysis","volume":"53","author":"Carriere","year":"2018","journal-title":"Health Place"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T12:48:01Z","timestamp":1732538881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024002830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2152265024002830"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.07.013","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic Myelomonocytic Leukemia and Atypical Chronic Myeloid Leukemia: A National Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}